Evidence map›Paper›PMID 35397079›Full record

SynthesisBreast cancer research and treatment2022

Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review.

Nhu Hanh To, Hoang Quy Nguyen, Allan Thiolat, Bisheng Liu, José Cohen, Nina Radosevic-Robin, Yazid Belkacemi, TransAtlantic Radiation Oncology Network (TRONE) & Association of Radiotherapy, and Oncology of the Mediterranean Area (AROME)

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nhu Hanh ToRadiation Oncology Department and Henri Mondor Breast Center, AP-HP, Henri Mondor University Hospital, 1 rue Gustave Eiffel, 94010, Créteil, France.
Hoang Quy NguyenDepartment of Medical Oncology 4, Ho Chi Minh City Oncology Hospital, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Allan ThiolatUniversity of Paris-Est Créteil (UPEC), Créteil, France.
Bisheng LiuRadiation Oncology Department and Henri Mondor Breast Center, AP-HP, Henri Mondor University Hospital, 1 rue Gustave Eiffel, 94010, Créteil, France.
José CohenUniversity of Paris-Est Créteil (UPEC), Créteil, France.
Nina Radosevic-Robin *Department of Pathology, Centre Jean Perrin, University Clermont Auvergne, INSERM U1240, Clermont-Ferrand, France.
Yazid Belkacemi *Radiation Oncology Department and Henri Mondor Breast Center, AP-HP, Henri Mondor University Hospital, 1 rue Gustave Eiffel, 94010, Créteil, France. yazid.belkacemi@aphp.fr.ORCID http://orcid.org/0000-0003-1343-8370
TransAtlantic Radiation Oncology Network (TRONE) & Association of Radiotherapy, and Oncology of the Mediterranean Area (AROME)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadiation therapy (RT) for triple-negative breast cancer (TNBC) treatment is currently delivered in the adjuvant setting and is under investigation as a booster of neoadjuvant treatments. However, TNBC radioresistance remains an obstacle, so new biomarkers are needed to select patients for any integration of RT in the TNBC therapy sequence. MicroRNAs (miRs) are important regulators of gene expression, involved in cancer response to ionizing radiation (IR) and assessable by tumor tissue or liquid biopsy. This systematic review aimed to evaluate the relationships between miRs and response to radiation in TNBC, as well as their potential predictive and prognostic values.

methodsA thorough review of studies related to miRs and RT in TNBC was performed on PubMed, EMBASE, and Web of Science. We searched for original English articles that involved dysregulation of miRs in response to IR on TNBC-related preclinical and clinical studies. After a rigorous selection, 44 studies were chosen for further analysis.

resultsThirty-five miRs were identified to be TNBC related, out of which 21 were downregulated, 13 upregulated, and 2 had a double-side expression in this cancer. Expression modulation of many of these miRs is radiosensitizing, among which miR-7, -27a, -34a, -122, and let-7 are most studied, still only in experimental models. The miRs reported as most influencing/reflecting TNBC response to IR are miR-7, -27a, -155, -205, -211, and -221, whereas miR-21, -33a, -139-5p, and -210 are associated with TNBC patient outcome after RT.

conclusionmiRs are emerging biomarkers and radiosensitizers in TNBC, worth further investigation. Dynamic assessment of circulating miRs could improve monitoring and TNBC RT efficacy, which are of particular interest in the neoadjuvant and the high-risk patients' settings.

Indexed as

Circulating MicroRNAMicroRNAsTriple Negative Breast NeoplasmsBiomarkersBiomarkers, TumorGene Expression Regulation, NeoplasticHumansRadiation ToleranceBiomarkersBiomarkers, TumorCirculating MicroRNAMicroRNAsmicroRNARadiation therapyRadioresistanceRadiosensitizationTriple-negative breast cancer

Identifiers

PMID35397079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.